View all news

Exicure, Inc. to Present at Upcoming Investor Conference and Participate in Oncology Roundtable


SKOKIE, Ill.--(BUSINESS WIRE)--Sep. 28, 2018-- Exicure, Inc. (OTCQB:XCUR), the pioneer in the development and application of three-dimensional Spherical Nucleic Acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, announced today that Dr. David Giljohann, Chief Executive Officer of Exicure, will present at the Ladenburg Thalmann 2018 Healthcare Conference and Leerink Partners Roundtable Series: Rare Disease & Oncology. Details of these presentations are as follows:

Ladenburg Thalmann 2018 Healthcare Conference

  • Date/Time: Tuesday, October 2, 2018 at 2:00 p.m. EDT
  • Location: Sofitel Hotel, New York City

Leerink Partners Roundtable Series: Rare Disease & Oncology

  • Date/Time: Wednesday, October 3, 2018 at 9:30 a.m. EDT
  • Location: Lotte New York Palace, New York City

A live webcast of these presentations will be available on the Events & Presentations section of Exicure's website, where it will also be archived and available for replay following the presentation for 30 days.

About Exicure, Inc.

Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. Exicure is based outside of Chicago, IL. For more information, please visit

Source: Exicure, Inc.

Media Contact:
MacDougall Biomedical Communications
Karen Sharma, 781-235-3060
Investor Contact:
The Del Mar Consulting Group, Inc.
Robert B. Prag, 858-794-9500

Multimedia Files:

Categories: Press Releases
View all news